Pulmonary Fibrosis Treatment in India – Antifibrotic Therapy & Transplant Evaluation

Pulmonary fibrosis treatment in India from $3,000. Pirfenidone, nintedanib, pulmonary rehabilitation, and lung transplant evaluation at specialist respiratory centres.

Estimated cost: $3,000 – $8,000 · Average stay: 7–14 days

Pulmonary fibrosis is a progressive lung disease in which the lung tissue becomes scarred and stiff, making breathing and oxygen absorption increasingly difficult. Idiopathic pulmonary fibrosis (IPF) is the most common form, but fibrosis can also result from autoimmune diseases, occupational exposures, medications, or infections.

While there is no cure, antifibrotic medications — pirfenidone and nintedanib — significantly slow disease progression. India's respiratory medicine specialists manage pulmonary fibrosis with evidence-based protocols, pulmonary rehabilitation, oxygen therapy, and, for appropriate patients, lung transplant evaluation — all at substantially lower cost than Western countries.

Generic antifibrotic drugs in India cost $200–$400 per month compared to $8,000–$12,000 per month in the US — making India the most cost-effective destination for long-term pulmonary fibrosis management.

What is Pulmonary Fibrosis?

Pulmonary fibrosis involves progressive replacement of normal lung tissue with scar tissue (fibrosis), reducing lung compliance and gas exchange capacity. Patients experience progressive breathlessness, dry cough, and fatigue. HRCT of the chest typically shows a basal-predominant usual interstitial pneumonia (UIP) pattern. Pulmonary function tests show a restrictive pattern with reduced diffusion capacity.

Diagnosis requires high-resolution CT, pulmonary function tests, and sometimes a surgical lung biopsy via VATS. A multidisciplinary team discussion — pulmonologist, radiologist, and pathologist — confirms the diagnosis and guides treatment selection.

Who Should Seek Treatment for Pulmonary Fibrosis?

Any patient with a confirmed or suspected diagnosis of IPF or other progressive fibrotic lung disease should seek expert evaluation. Early treatment initiation gives the best outcomes — do not wait until breathlessness is severe. Patients with FVC declining by more than 10% in 12 months, resting oxygen requirement, or walk distance below 250 metres should also be urgently evaluated for lung transplant listing.

How is Pulmonary Fibrosis Treated?

Treatment is personalised after thorough baseline assessment. Antifibrotic therapy (pirfenidone or nintedanib) is started and dose-titrated based on tolerability and lung function trajectory. Pulmonary rehabilitation — a structured programme of supervised exercise, breathing techniques, and education — improves exercise capacity and quality of life. Supplemental oxygen is prescribed for resting or exertional hypoxaemia.

For patients with severe disease, transplant evaluation assesses candidacy for single or bilateral lung transplant. Specialist palliative pulmonology manages symptoms in advanced cases. Gastro-oesophageal reflux treatment is recommended as an evidence-based adjunct to slow fibrosis progression.

Procedure Steps

1. Baseline assessment: HRCT chest, spirometry, DLCO, six-minute walk test, arterial blood gas
2. Multidisciplinary team discussion: pulmonologist, radiologist, pathologist
3. VATS surgical lung biopsy if histological confirmation required
4. Antifibrotic therapy initiation: pirfenidone or nintedanib with dose titration
5. Pulmonary rehabilitation: 8–12 week supervised exercise and education programme
6. Oxygen prescription: ambulatory, resting, and nocturnal as required
7. Six-monthly disease monitoring: repeat PFTs, HRCT, 6MWT, quality-of-life scoring
8. Gastro-oesophageal reflux treatment as evidence-based adjunct
9. Transplant evaluation for eligible patients: cardiac assessment, nutritional optimisation
10. Palliative care integration for symptom management in advanced disease

Cost Comparison Worldwide

Country — Range — Savings

--- — --- — ---

India — $3,000 – $8,000 — Save 90%

UAE — $15,000 – $40,000 — Save 80%

United States — $30,000 – $80,000 — —

United Kingdom — $20,000 – $50,000 — —

Initial evaluation, treatment initiation, and one year of monitoring in India costs $3,000–$8,000. Annual antifibrotic medication (pirfenidone/nintedanib) costs $2,400–$4,800/year in India versus $96,000–$144,000/year in the US — a 97% saving. India is the most cost-effective destination for long-term pulmonary fibrosis management.

Recovery & Follow-up

Pulmonary fibrosis is a chronic condition managed rather than cured. With antifibrotic therapy, most patients experience a slower rate of FVC decline. Pulmonary rehabilitation improves exercise tolerance and quality of life within 8–12 weeks. Oxygen therapy reduces breathlessness and allows more active daily living. Regular monitoring every six months tracks disease trajectory and adjusts treatment accordingly.

Recovery Tips

• Take antifibrotic medication with food to reduce gastrointestinal side effects.
• Complete the full pulmonary rehabilitation programme — attendance at all sessions maximises benefit.
• Use supplemental oxygen during exertion even if resting saturation is acceptable.
• Treat any gastro-oesophageal reflux promptly — acid microaspiration accelerates fibrosis.
• Get annual influenza and pneumococcal vaccinations to prevent respiratory infections.

Risks & Complications

Antifibrotic therapy side effects include nausea, photosensitivity (pirfenidone), and diarrhoea or hepatotoxicity (nintedanib). These are usually manageable with dose adjustment. Pulmonary rehabilitation is very safe but should be supervised to avoid over-exertion. Lung transplant carries significant surgical and long-term immunosuppression risks — discussed separately with the transplant team.

Why GAF Healthcare

Gaf Healthcare arranges specialist respiratory consultations, pre-travel review of imaging, diagnostic workup coordination, oxygen supply during travel and in-country, and a long-term management plan prepared in collaboration with your home respiratory physician. We ensure continuity of antifibrotic medication supply.

Frequently Asked Questions

Can pulmonary fibrosis be cured?

Currently there is no cure for IPF or most fibrotic lung diseases. However, antifibrotic medications significantly slow disease progression. Lung transplantation offers the possibility of restored lung function in carefully selected patients.

Are antifibrotic drugs available in India at affordable prices?

Yes. Generic pirfenidone and nintedanib are manufactured in India at 97% lower cost than branded versions in the US. Our team can arrange a continued supply plan for after you return home.

How effective is pulmonary rehabilitation for pulmonary fibrosis?

Pulmonary rehabilitation significantly improves exercise capacity, dyspnoea scores, and quality of life in IPF patients. Effects are maintained for 6–12 months and are cumulative with repeated programmes.

When should I consider a lung transplant for pulmonary fibrosis?

Transplant evaluation is recommended when FVC falls below 50–60% predicted, DLCO below 40%, resting oxygen requirement develops, or six-minute walk distance drops below 250 metres.

How does Gaf Healthcare support pulmonary fibrosis patients?

We arrange specialist consultations, coordinate diagnostic workup ahead of travel, organise oxygen supply during and after travel, and prepare a long-term management plan in collaboration with your home respiratory physician.